Sanofi withdraws and refiles pre-merger notification, report form to acquire Provention Bio
- Sanofi (NASDAQ:SNY) said it had withdrawn and refiled its pre-merger notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its pending acquisition of Provention Bio.
- Sanofi said last month it would buy all outstanding shares of common stock of Provention Bio for $25 per Share.
- Sanofi had elected to withdraw and refile its pre-merger notification and report form, which was initially filed on March 24, to provide the Federal Trade Commission with additional time for review.
- The acquisition is expected to close in the second quarter of 2023.